Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,609.78
(
0.13%
)
US TECH 100
29,808.40
(
0.33%
)
Dow Jones
51,307.79
(
0.45%
)
Brent Oil
96.03
(
0.81%
)
Bitcoin
66,631.82
(
-0.08%
)
News Focus
News Focus
Post# of 519111
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Investor2014

Send PM Follow Ignore
Followers 65
Posts 27927
Boards Moderated 0
Alias Born 11/23/2016

Investor2014

Re: XenaLives post# 176141

Wednesday, 12/26/2018 9:24:32 AM

Wednesday, December 26, 2018 9:24:32 AM

Post# of 519111
You would think so.

The company has also successfully activated 75% of all planned clinical study sites representing 9 clinical trial sites for the Phase 2b/3 ANAVEX2-73 Alzheimer disease study. Enrollment and dosing of patients is currently proceeding as planned.


Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q4 2018 Results - Earnings Call Transcript
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News